MX359207B - Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo. - Google Patents

Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo.

Info

Publication number
MX359207B
MX359207B MX2014014622A MX2014014622A MX359207B MX 359207 B MX359207 B MX 359207B MX 2014014622 A MX2014014622 A MX 2014014622A MX 2014014622 A MX2014014622 A MX 2014014622A MX 359207 B MX359207 B MX 359207B
Authority
MX
Mexico
Prior art keywords
pyrrolo
triazine compound
preparation
application
general formula
Prior art date
Application number
MX2014014622A
Other languages
English (en)
Other versions
MX2014014622A (es
Inventor
Chen Yi
Ding Jian
Yang Chunhao
Meng Linghua
Chen Yanhong
Wang Xiang
Tan Cun
Li Jiapeng
Original Assignee
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica Cas filed Critical Shanghai Inst Materia Medica Cas
Publication of MX2014014622A publication Critical patent/MX2014014622A/es
Publication of MX359207B publication Critical patent/MX359207B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se relaciona con el compuesto pirrolo[2,1-f][1,2,4]triazina, un isómero del mismo o una sal farmacéuticamente aceptable, éster o hidrato del mismo, y un método de preparación y de aplicación del mismo. El compuesto de pirrolo[2,1-f][1,2,4]triazina tiene una estructura expresada en la fórmula general (I). El compuesto de pirrolo[2,1-f][1,2,4]triaz ina expresado en la fórmula general (I) puede inhibir una fosfatidilinosito-3 cinasa relacionada con enfermedades de tipo cáncer.
MX2014014622A 2012-05-31 2013-04-23 Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo. MX359207B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210177980.3A CN103450204B (zh) 2012-05-31 2012-05-31 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
PCT/CN2013/074559 WO2013177983A1 (zh) 2012-05-31 2013-04-23 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Publications (2)

Publication Number Publication Date
MX2014014622A MX2014014622A (es) 2015-08-10
MX359207B true MX359207B (es) 2018-09-19

Family

ID=49672377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014622A MX359207B (es) 2012-05-31 2013-04-23 Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo.

Country Status (14)

Country Link
US (1) US9447101B2 (es)
EP (1) EP2857403B1 (es)
JP (1) JP6067107B2 (es)
KR (1) KR101824299B1 (es)
CN (1) CN103450204B (es)
AU (1) AU2013270326B2 (es)
BR (1) BR112014029708B1 (es)
CA (1) CA2874062C (es)
ES (1) ES2703934T3 (es)
HK (1) HK1203499A1 (es)
MX (1) MX359207B (es)
RU (1) RU2589053C1 (es)
SG (1) SG11201407752YA (es)
WO (1) WO2013177983A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
EP2948454B1 (en) 2013-01-24 2017-05-31 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Triazine compounds and a process for preparation thereof
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017040448A1 (en) * 2015-08-31 2017-03-09 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CA3028822C (en) * 2016-06-25 2021-06-22 Suzhou Kintor Pharmaceuticals, Inc. Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
KR20200041361A (ko) * 2017-08-15 2020-04-21 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Fgfr 억제제 및 그의 의학적 용도
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
MX2022003217A (es) 2019-09-19 2022-06-29 Totus Medicines Inc Conjugados terapeuticos.
CN112851563A (zh) * 2020-12-30 2021-05-28 安徽金鼎医药股份有限公司 N-氨基-3-氮杂双环[3,3,0]辛烷盐酸盐的合成工艺
WO2023035614A1 (zh) * 2021-09-10 2023-03-16 上海海和药物研究开发股份有限公司 包含PI3Kα抑制剂的药物组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7619083B2 (en) 2005-07-01 2009-11-17 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
DK2050749T3 (en) * 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
KR101460816B1 (ko) * 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
US8148522B2 (en) 2007-01-02 2012-04-03 Bristol-Myers Squibb Company Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
EP2212333A1 (en) * 2007-10-16 2010-08-04 Wyeth LLC Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
WO2010092340A1 (en) * 2009-02-13 2010-08-19 Ucb Pharma S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
EP2419429B1 (en) * 2009-04-16 2014-03-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines as inhibitors of protein kinases
EP2526102B1 (en) * 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20130131057A1 (en) * 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途

Also Published As

Publication number Publication date
BR112014029708A8 (pt) 2021-09-08
HK1203499A1 (en) 2015-10-30
ES2703934T3 (es) 2019-03-13
WO2013177983A1 (zh) 2013-12-05
CN103450204B (zh) 2016-08-17
BR112014029708B1 (pt) 2023-05-02
EP2857403A1 (en) 2015-04-08
AU2013270326B2 (en) 2016-07-14
CA2874062A1 (en) 2013-12-05
US9447101B2 (en) 2016-09-20
KR20150009565A (ko) 2015-01-26
SG11201407752YA (en) 2015-01-29
RU2589053C1 (ru) 2016-07-10
JP6067107B2 (ja) 2017-01-25
JP2015518010A (ja) 2015-06-25
EP2857403A4 (en) 2015-10-21
KR101824299B1 (ko) 2018-03-14
US20150141644A1 (en) 2015-05-21
MX2014014622A (es) 2015-08-10
CA2874062C (en) 2015-09-22
EP2857403B1 (en) 2018-10-10
CN103450204A (zh) 2013-12-18
BR112014029708A2 (pt) 2017-06-27
AU2013270326A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
AU2013270326B2 (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
PH12015502563A1 (en) Bipyrazole derivatives as jak inhibitors
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
CA2871471C (en) Dna-pk inhibitors
CA2903881C (en) Tricyclic heterocycles as bet protein inhibitors
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
WO2014016849A3 (en) Novel triazine compounds
WO2013040227A3 (en) Therapeutic compounds
PH12014502547A1 (en) Dosage regimen for a pi-3 kinase inhibitor
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
MX362905B (es) Tratamiento de combinacion.
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2014030142A3 (en) Nitroimidazole compounds and their use in cancer therapy

Legal Events

Date Code Title Description
FG Grant or registration